Examples of 'progression-free survival' in a sentence
Meaning of "progression-free survival"
Progression-free survival (PFS) is a term commonly used in medical and clinical research. It refers to the length of time during and after treatment for a disease, such as cancer, in which the disease does not worsen or progress. PFS is an important measure in assessing the effectiveness of treatments and is often discussed in the field of oncology
How to use "progression-free survival" in a sentence
Basic
Advanced
progression-free survival
Progression-free survival was the primary endpoint.
The main measure of effectiveness was progression-free survival.
Median progression-free survival by independent assessment.
The treatment goal at present is progression-free survival.
Progression-free survival was better with sunitinib.
Statistically significant improvements in progression-free survival were also observed.
Median progression-free survival not reached yet.
However a statistically significant effect was seen on progression-free survival.
Progression-free survival was an exploratory endpoint.
A statistically significant improvement in progression-free survival was also observed.
Progression-free survival corresponds to absence of local or distance failure.
Approval will be based on a primary endpoint of progression-free survival.
Progression-free survival by time from last platinum therapy to recurrence.
We saw a more than doubling in median progression-free survival.
Progression-free survival assessed by biochemistry, radiology and immunology tests.
See also
Their possibility of improved progression-free survival and overall survival.
Progression-free survival rates are an indication of how effective a particular treatment is.
The primary efficacy endpoint of the study is progression-free survival.
The median progression-free survival has not yet been reached.
It is remarkably well tolerated and results in longer progression-free survival.
Secondary endpoints included progression-free survival and objective response rate.
In an embodiment the administration of the combination increases progression-free survival.
These indexes include progression-free survival and observed survival rates.
Another well accepted marker for efficacy is progression-free survival.
Progression-free survival was also improved with pirfenidone compared with placebo.
Primary outcomes were overall survival and radiographic progression-free survival.
The primary end point was progression-free survival as assessed by an independent review committee.
The secondary endpoints are overall survival and progression-free survival.
Information on progression-free survival and health-related quality of life were not available.
The combination did not show a statistically significant improvement in progression-free survival.
The co-primary study endpoints were progression-free survival and overall survival.
These expanded indications are approved under accelerated approval based on progression-free survival.
To evaluate the duration of response, progression-free survival and overall survival.
The median progression-free survival among all the patients was about a year.
The secondary objectives included progression-free survival and drug safety.
In some embodiments of the methods of the invention, the administrations increase progression-free survival.
It is an active agent whose effect on progression-free survival has now been established.
When used following chemotherapy and radiation, it was found to improve progression-free survival.
Secondary outcome measures included progression-free survival and objective response rate.
The primary efficacy parameter of the trial was the duration of progression-free survival.
Progression-free survival denotes the chances of staying free of disease progression after a particular treatment.
Detecting an overall survival benefit that is derived from progression-free survival.
Progression-free survival was also longer in the combination treatment group compared to the single-therapy group.
Co-primary efficacy endpoints were overall survival and radiographic progression-free survival rPFS.
Progression-free survival and overall survival in patients with stage IV and selected.
We need to do more than classify patients based on progression-free survival or overall survival.
Kaplan-Meier curve of progression-free survival by independent assessment for the overall population.
The primary endpoints of the trial were objective response rate and progression-free survival.
Findings regarding response rate and progression-free survival are provided in Table 3.
Cross-trial comparisons indicate that afatinib provides the longest progression-free survival.
You'll also be interested in:
Examples of using Progression-free
Show more
Progression-free survival was the primary endpoint
The main measure of effectiveness was progression-free survival
Median progression-free survival by independent assessment
Examples of using Survival
Show more
Right to life and survival and development
The survival of each of these children is a miracle
It is vital for the survival of million people
